J&J stepped in with a blockbuster licensing deal for Pharmacyclics' late-stage blood cancer drug ibrutinib late last year, and ever since it's been keeping up a rich flow of milestone payments promised in the $975 million deal.
Pfizer doesn't want CEO Ian Read to take the stand in a Chantix liability suit. That's not unusual; Johnson & Johnson fought a request that CEO Alex Gorsky testify in person in a trial over alleged Risperdal misconduct. What's different in Pfizer's case is that a judge actually ordered Read to appear.
Cordis, a unit of Johnson & Johnson is seeking an expanded indication for its SMART self-expanding stent, and the device performed well in patients with obstructive superficial femoral artery disease in a 12-month study.
Now that they've completed their stints in federal prison, four former Synthes executives have been essentially banished from the healthcare industry for their roles in the Norian bone cement scandal that left three dead.
Goldman Sachs analyst Jami Rubin can be tough to please. Particularly for companies that aren't jazzed about the idea of splitting themselves into smaller pieces. Hear that, Johnson & Johnson ($JNJ)?
Johnson & Johnson ($JNJ) has been struggling with Doxil supplies for months. As one of the standard treatments for ovarian cancer, the drug has been sorely missed as supplies ran short. Now, the company is asking regulators to approve a new plan to boost supplies, at least in the short term.
Johnson & Johnson has again backed down on its defense of Risperdal cases alleging that it caused boys who were given the antipsychotic to grow breasts.
Lawyers are pulling no punches in that Risperdal litigation playing out in Philadelphia court. After trying to force Johnson & Johnson CEO Alex Gorsky onto the stand to talk about the company's Risperdal marketing practices, plaintiff's attorneys want ex-FDA chief David Kessler to testify--and Kessler is on record saying that J&J's Janssen unit broke the law by marketing Risperdal off-label.
Janssen Pharmaceutica is making its European supply chain operations more efficient with a new distribution hub in Belgium that funnels production from a number of European plants into a single location.
Drug development is a tough business. Sometimes, just when you think you're getting to the pot at the end of the rainbow, you find the trap door one step away. It's not supposed to work that...